CA2213906A1 - Composition pharmaceutique et methode pour sauvegarder les neurones au cours d'un accident cerebro-vasculaire ischemique - Google Patents

Composition pharmaceutique et methode pour sauvegarder les neurones au cours d'un accident cerebro-vasculaire ischemique

Info

Publication number
CA2213906A1
CA2213906A1 CA 2213906 CA2213906A CA2213906A1 CA 2213906 A1 CA2213906 A1 CA 2213906A1 CA 2213906 CA2213906 CA 2213906 CA 2213906 A CA2213906 A CA 2213906A CA 2213906 A1 CA2213906 A1 CA 2213906A1
Authority
CA
Canada
Prior art keywords
csf
microspheres
neurons
disease
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2213906
Other languages
English (en)
Inventor
Dusica Maysinger
Sergey Fedoroff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2213906A1 publication Critical patent/CA2213906A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
CA 2213906 1996-09-23 1997-08-25 Composition pharmaceutique et methode pour sauvegarder les neurones au cours d'un accident cerebro-vasculaire ischemique Abandoned CA2213906A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2656096P 1996-09-23 1996-09-23
US60/026,560 1996-09-23

Publications (1)

Publication Number Publication Date
CA2213906A1 true CA2213906A1 (fr) 1998-03-23

Family

ID=21832512

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2213906 Abandoned CA2213906A1 (fr) 1996-09-23 1997-08-25 Composition pharmaceutique et methode pour sauvegarder les neurones au cours d'un accident cerebro-vasculaire ischemique

Country Status (1)

Country Link
CA (1) CA2213906A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002047664A2 (fr) * 2000-12-13 2002-06-20 Merckle Gmbh Microparticules presentant un meilleur profil de liberation et procede de fabrication
EP1374898A1 (fr) * 2001-03-12 2004-01-02 Institute of Gene and Brain Science Remedes pour lesions nerveuses
EP1948246A2 (fr) * 2005-11-14 2008-07-30 Enterprise Partners Venture Capital Thérapie par facteur de cellules souches pour lésion tissulaire
EP2186525A3 (fr) * 2002-12-31 2011-02-09 SYGNIS Bioscience GmbH & Co KG G-CSF pour son utilisation dans le traitement de la maladie de Parkinson
EP2701727A2 (fr) * 2011-03-04 2014-03-05 The Regents of the University of California Facteurs de croissance libérés localement pour favoriser la récupération motrice après un accident vasculaire cérébral
CN107115314A (zh) * 2011-06-02 2017-09-01 加利福尼亚大学董事会 膜包封的纳米颗粒及使用方法

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002047664A3 (fr) * 2000-12-13 2002-12-27 Merckle Gmbh Microparticules presentant un meilleur profil de liberation et procede de fabrication
WO2002047664A2 (fr) * 2000-12-13 2002-06-20 Merckle Gmbh Microparticules presentant un meilleur profil de liberation et procede de fabrication
EP1374898A1 (fr) * 2001-03-12 2004-01-02 Institute of Gene and Brain Science Remedes pour lesions nerveuses
EP1374898A4 (fr) * 2001-03-12 2004-07-28 Inst Of Gene And Brain Science Remedes pour lesions nerveuses
US8053407B2 (en) 2002-12-31 2011-11-08 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoeitic growth factors
US8071543B2 (en) 2002-12-31 2011-12-06 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoeitic growth factors
EP2186525A3 (fr) * 2002-12-31 2011-02-09 SYGNIS Bioscience GmbH & Co KG G-CSF pour son utilisation dans le traitement de la maladie de Parkinson
EP1948246A2 (fr) * 2005-11-14 2008-07-30 Enterprise Partners Venture Capital Thérapie par facteur de cellules souches pour lésion tissulaire
EP1948246A4 (fr) * 2005-11-14 2010-04-28 Entpr Partners Venture Capital Thérapie par facteur de cellules souches pour lésion tissulaire
US8404653B2 (en) 2005-11-14 2013-03-26 Enterprise Partners Venture Capital Membrane bound stem cell factor therapy for ischemic heart
EP2701727A2 (fr) * 2011-03-04 2014-03-05 The Regents of the University of California Facteurs de croissance libérés localement pour favoriser la récupération motrice après un accident vasculaire cérébral
EP2701727A4 (fr) * 2011-03-04 2014-09-03 Univ California Facteurs de croissance libérés localement pour favoriser la récupération motrice après un accident vasculaire cérébral
AU2012225784B2 (en) * 2011-03-04 2016-03-17 The Regents Of The University Of California Locally released growth factors to mediate motor recovery after stroke
US9700596B2 (en) 2011-03-04 2017-07-11 The Regents Of The University Of California Locally released growth factors to mediate motor recovery after stroke
CN107115314A (zh) * 2011-06-02 2017-09-01 加利福尼亚大学董事会 膜包封的纳米颗粒及使用方法
CN107115314B (zh) * 2011-06-02 2022-04-29 加利福尼亚大学董事会 膜包封的纳米颗粒及使用方法

Similar Documents

Publication Publication Date Title
Berezovskaya et al. The hematopoietic cytokine, colony-stimulating factor 1, is also a growth factor in the CNS: congenital absence of CSF-1 in mice results in abnormal microglial response and increased neuron vulnerability to injury
Begum et al. Selective knockout of astrocytic Na+/H+ exchanger isoform 1 reduces astrogliosis, BBB damage, infarction, and improves neurological function after ischemic stroke
Sagot et al. Polymer encapsulated cell lines genetically engineered to release ciliary neurotrophic factor can slow down progressive motor neuronopathy in the mouse
Hoffman et al. NGF released from a polymer matrix prevents loss of ChAT expression in basal forebrain neurons following a fimbria-fornix lesion
Lehrmann et al. Cytokines in cerebral ischemia: expression of transforming growth factor beta-1 (TGF-β1) mRNA in the postischemic adult rat hippocampus
MANTHOFIPE et al. Astroglial cell contributions to neuronal survival and neuritic growth
Fournier et al. Biocompatibility of implantable synthetic polymeric drug carriers: focus on brain biocompatibility
US6287558B1 (en) Devices containing cells or tissue and an agent that inhibits damage by a host cell molecule
Oby et al. The blood–brain barrier and epilepsy
Krum et al. VEGF mRNA and Its Receptorflt-1Are Expressed in Reactive Astrocytes Following Neural Grafting and Tumor Cell Implantation in the Adult CNS
US6368612B1 (en) Devices for cloaking transplanted cells
JP2001519692A (ja) 非ステロイド性抗炎症剤による、移植装置に対する線維形成応答の阻害
Maysinger et al. Microencapsulated nerve growth factor: effects on the forebrain neurons following devascularizing cortical lesions
Berezovskaya et al. Colony stimulating factor-1 potentiates neuronal survival in cerebral cortex ischemic lesion
Furuta et al. Laminar segregation of the cortical plate during corticogenesis is accompanied by changes in glutamate receptor expression
Johnston et al. Trophic factor secreting kidney cell lines: in vitro characterization and functional effects following transplantation in ischemic rats
Coltman et al. Temporal characterization of microglia, II-1β-like immunoreactivity and astrocytes in the dentate gyrus of hippocampal organotypic slice cultures
CA2213906A1 (fr) Composition pharmaceutique et methode pour sauvegarder les neurones au cours d'un accident cerebro-vasculaire ischemique
Stark et al. Distribution of TGF-β, the TGF-β type I receptor and the R-II receptor in peripheral nerves and mechanoreceptors; observations on changes after traumatic injury
Gladilin et al. Ebselen lowers plasma interleukin-6 levels and glial heme oxygenase-1 expression after focal photothrombotic brain ischemia
Munekawa et al. Development of astroglial elements in the suprachiasmatic nucleus of the rat: with special reference to the involvement of the optic nerve
KR100699286B1 (ko) 뇌 종양 치료용 알긴산염 캡슐
Di Prospero et al. Suramin disrupts the gliotic response following a stab wound injury to the adult rat brain
Rosenstein Permeability to blood‐borne protein and 3HGABA in CNS tissue grafts. I. Intraventricular grafts
US20020192194A1 (en) Production and use of dopaminergic cells to treat dopaminergic deficiencies

Legal Events

Date Code Title Description
FZDE Dead